RenovoRx Q1 revenue ~$200K from RenovoCath sales; TIGeR-PaC trial 91 patients randomized

RenovoRx, Inc.

2025-Q1 EPS reported -$0.08 revenue$197,000

Q1 2025 revenue of ~$200K from commercial RenovoCath sales, exceeding internal expectations; gross profit $103K.
Cash $14.6M as of Mar 31, 2025, up from $7.2M at Dec 31, 2024; funds commercial scale-up and trial completion.
Phase III TIGeR-PaC trial: 91 patients randomized, 56 events (second interim analysis triggered); DMC review expected Q3 2025.
Net loss $2.4M vs $1.1M in Q1 2024 due to higher operating costs and lower warrant liability gain.
Management and Board purchased ~143K shares; new U.S. patent issued for TAMP platform (19 patents total).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.